MADRID (EUROPA PRESS).- The British government signed an agreement with the German pharmaceutical company BioNTech to carry out clinical trials on personalized vaccines against cancer combined with immunotherapy in up to 10,000 patients by 2030.
To help carry out this research, BioNTech plans to establish new laboratories in Cambridge, with an expected capacity of more than 70 highly qualified scientists, as well as a new regional center for the UK. BioNTech has already started conducting clinical trials in the British country and more trials will be launched, although most patients are expected to enroll from 2026.
“This landmark agreement brings us one step closer to delivering life-saving new cancer treatments to thousands of patients across the country. Personalized cancer vaccines have the potential to completely revolutionize the way we treat this disease.” cruel disease and it is with great satisfaction that, thanks to today’s announcement, clinical trials will be extended widely,” said British Prime Minister Rishi Sunak.
The trials will focus on mRNA-based personalized cancer immunotherapies, a type of cancer treatment that activates a patient’s immune system and can be designed to combat abnormalities common to a specific type of cancer or be tailored to each individual’s tumor.
Personalized immunotherapies are created by analyzing a patient’s tumor to identify mutations specific to their cancer and, from that information, create an immunotherapy tailored to the patient.
“The UK’s experience in genomic analysis of cancer patients is an essential component of our joint effort to make precision, mRNA-based cancer immunotherapies widely accessible through clinical trials. If successful, This collaboration has the potential to improve outcomes for cancer patients not only in the UK, but also around the world,” said Ugur Sahin, CEO and Co-Founder of BioNTech.
